Terlipressin Administration for Hepatorenal Syndrome

Efficacy and Administration

The American Society of Anesthesiologists recommends continuous infusion of terlipressin over bolus dosing for hepatorenal syndrome, as it remains equally effective while enabling lower daily doses and reducing the risk of adverse events such as cardiac or intestinal ischemia, pulmonary edema, and distal necrosis 1, 2
Both administration methods demonstrate similar efficacy in improving renal function in hepatorenal syndrome patients, with response rates ranging from 64% to 76% with terlipressin treatment 1, 2

Continuous infusion provides a more stable lowering effect on portal pressure compared to bolus dosing, and allows for lower daily doses while maintaining efficacy, thereby reducing the risk of adverse events 1, 2, 3
Adverse events such as cardiac or intestinal ischemia, pulmonary edema, and distal necrosis occur less frequently with continuous infusion 1, 2

Initial dose for bolus dosing: 0.5-1 mg every 4-6 hours by intravenous bolus, with dose escalation up to 2 mg every 4-6 hours if serum creatinine does not decrease by more than 25% 1, 2, 3
Initial dose for continuous infusion: 2 mg/day as continuous intravenous infusion, with dose adjustment based on clinical response and serum creatinine levels 1, 3, 4

Terlipressin should always be administered with albumin for optimal results in hepatorenal syndrome, with recommended albumin dosing: 1 g/kg on first day, followed by 20-40 g/day 1, 2, 3, 4

Response should be assessed by monitoring serum creatinine levels, with complete response defined as serum creatinine below 1.5 mg/dl, and partial response defined as decrease of serum creatinine ≥50% with final value still higher than 1.5 mg/dl 1, 2, 3

Common adverse effects include diarrhea, abdominal pain, circulatory overload, and cardiovascular ischemic complications, with adverse events occurring in up to 45-46% of patients when terlipressin is delivered by IV boluses 3
Careful clinical screening including electrocardiogram is recommended before starting treatment, and terlipressin is contraindicated in patients with hypoxemia (SpO2 <90%) 3, 4